MDXH, BE0974461940

MDxHealth stock heads into November results with a USD 30.8 million cap

Published on 10/08/2026 at 03:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MDxHealth stock enters November with first-half revenue of USD 51.1 million, up 14 percent from the prior-year period. The operating loss widened to USD 13.3 million.

MDXH, BE0974461940, Illustration mit AI erstellt.

MDxHealth stock (ISIN BE0974461940) carried a market capitalization of USD 30.8 million on Nasdaq on October 7, 2026. The share was last at USD 0.60 at 4:00 p.m. ET, while the next reporting date is set for November 10, 2026.

Revenue grows in the first half

According to IT Boltwise on September 30, 2026, revenue from continuing operations rose 14 percent year over year to USD 51.1 million in the first half of 2026. Gross profit increased 7 percent to USD 32.6 million, but the gross margin fell from 67.9 percent to 63.7 percent.

The comparison points to a clear split in the latest operating picture. Revenue expanded by USD 6.3 million from the prior-year period, while lower gross margin limited the conversion of that growth into earnings.

Losses and cash shape the outlook

The operating loss widened from USD 6.2 million in the first half of 2025 to USD 13.3 million in the first half of 2026, according to IT Boltwise. Net loss from continuing operations reached USD 19.2 million, while cash and cash equivalents stood at USD 19.2 million on June 30, 2026.

MDxHealth also raised USD 20.0 million through an August 13, 2026 share placement of 44,052,862 new shares at USD 0.454 each. That financing added liquidity, but the larger share count increases the importance of revenue growth and margin control in the November report.

Analysts see a higher valuation

Investing.com lists a Buy consensus based on five analysts, with an average 12-month price target of USD 1.800, a high of USD 3.00 and a low of USD 1.00. The average target lies 200 percent above the Nasdaq price of USD 0.60, making the distance between expectations and the quoted share value a central risk marker.

MDxHealth operates in molecular diagnostics, with products focused on prostate cancer testing and other precision-diagnostic applications. Its financial reports use IFRS and US dollars, according to the company's investor-relations information.

Nasdaq price remains the key checkpoint

MDxHealth's 52-week range was USD 0.40 to USD 5.33 as of October 7, 2026, and trading volume reached 330,664 shares. The November 10 report will put the 14 percent revenue increase, the 63.7 percent gross margin and the USD 13.3 million operating loss into the next period's context.